Delivery Order SPE2DB22D9112-SPE2DB24FE6SX

Award Date 4/3/24
Potential Completion Date 4/24/24
Potential Value $3.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $25,728.84 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the delivery of 4,565,176,099 units of the NEXPLANON 68 MG IMPLANTS contraceptive product. This delivery order is part of a larger single-award indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA, which runs through December 31, 2025. The IDC allows the DLA to issue...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $29,587.68 and an ultimate completion date of October 3, 2022. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999, which runs through December 31, 2025. The...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth up to $4,288.14 to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of 4,564,134,203 units of the NEXPLANON 68 MG IMPLANTS contraceptive product. This order was placed against DMS Pharmaceutical Group's existing indefinite delivery contract SPE2DB with the DLA, valued at up to $4,999,999 through 2025. The DLA utilizes this vehicle to issue delivery...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4,565,711,445 units of NEXPLANON 68 MG IMPLANTS. The delivery order, valued at $35,734.50, was issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, which has a ceiling value of up to $499,999,999 and runs through December 31, 2025. DMS Pharmaceutical Group is a key supplier in the federal...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of NEXPLANON 68 MG IMPLANTS. The firm fixed-price contract has a ceiling value of $7,146.90 and an ultimate completion date of April 2, 2024. This award is made under DMS Pharmaceutical Group's existing indefinite delivery contract SPE2DB22D9207 with DLA, valued up to $4,999,999 through 2025, which enables the agency to issue delivery orders for...
The U.S. Department of Defense, through the Defense Logistics Agency (DLA), awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the procurement of 68 mg NEXPLANON contraceptive implants. The contract, valued at $4,288.14, has an ultimate completion date of April 3, 2024. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, 4600082013 under the SPE2DB program, with a ceiling value of up to $4,999,999...
The U.S. Defense Logistics Agency awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of 68 mg NEXPLANON contraceptive implants. The contract, valued at $35,734.50, has an ultimate completion date of April 8, 2024. This delivery order is placed under DMS Pharmaceutical Group's existing Indefinite Delivery Contract SPE2DB24FZR56 with the Defense Logistics Agency, which is valued at up to $4,999,999 through the end of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the procurement of NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $4,288.14 and a period of performance through March 7, 2024. This delivery order contract is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999, which enables the...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $3,689.76 and an ultimate completion date of October 17, 2022. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc., valued at up to $499,999,999, which runs through December 31, 2025. The IDC allows the DLA to...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4,563,181,463 units of the contraceptive implant NEXPLANON 68 MG. The $8,204.88 delivery order is part of a larger indefinite delivery contract held by DMS Pharmaceutical Group Inc. to supply pharmaceuticals and medical products to DLA Troop Support Medical facilities worldwide. The contract does not have a set-aside designation and has a...
  • SPE2DB22D9112
    Indefinite Delivery Contract
  • SPE2DB22D9112-SPE2DB24FE6SX
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4,564,185,524 NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $3,573.45 and a period of performance through April 24, 2024. This delivery order is part of a larger indefinite delivery contract (SPE2DB22D9112) held by DMS Pharmaceutical Group with the DLA, valued up to $4,999,999, which enables the agency to place orders for a broad range of pharmaceutical products to support military health facilities globally. The contract does not have a set-aside designation.

Generated 7/3/24, 10:03 AM